规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
体外研究 (In Vitro) |
同样,使用来自肿瘤引流淋巴结的表达 IDO 的小鼠 DC,Navoximod 在体外消除了 IDO 诱导的抗原特异性 T 细胞 (OT-I) 抑制,ED50=120 nM[1]。在同种异体混合淋巴细胞反应 (MLR) 反应中使用表达 IDO 的人单核细胞衍生的树突状细胞 (DC),Navoximod (NLG919) 有效阻断 IDO 诱导的 T 细胞抑制并恢复强大的 T 细胞反应,ED50 = 80 nM。 navoximod 的 EC50 为 0.95 μM,以浓度依赖性方式抑制 IDO 活性。与游离的 Navoximod 相比,PEG2k-Fmoc-NLG(L) 对 IDO 抑制的 EC50 较低,为 3.4 μM,但 PEG2k-Fmoc-NLG(S) 的 EC50 最低,>10 μM。 IDO+肿瘤细胞与 BALB/c 小鼠脾细胞共培养可显着抑制 T 细胞增殖。当纳伏昔莫德给予混合细胞时,这种抑制作用大大减弱。尽管效果略低于纳伏昔莫德,但 PEG2k-Fmoc-NLG(L) 在逆转肿瘤细胞的抑制作用方面同样具有活性 [3]。
|
||
---|---|---|---|
体内研究 (In Vivo) |
vNavoximod (NLG919) 具有口服生物利用度 (F>70%),具有良好的药代动力学和毒理学特征。小鼠单次口服剂量的 navoximod 可使组织 Kyn 和血浆浓度降低约 50%。在携带大型 B16F10 肿瘤的小鼠体内,用 IFA 中的同源 hgp100 肽加 CpG-1826 进行免疫后,Navoximod 治疗显着增加了幼稚静息 pmel-1 细胞的抗肿瘤反应。与仅接受 pmel-1/疫苗而不接受纳伏昔莫德的对照小鼠相比,纳伏昔莫德加 pmel-1/疫苗导致免疫后 4 天内肿瘤生长显着下降(肿瘤体积减少约 95%)[1]。与单独使用 NSC 362856 (TMZ)+RT 治疗的小鼠相比,Navoximod 和 D-1MT (Indoximod) 与这些治疗配对时均可提高生存率[2]。
|
||
动物实验 |
|
||
参考文献 |
[1]. Mario R. Mautino, et al. Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. AACR 104th Annual Meeting 2013; Apr 6-10, 2013.
[2]. Li M, et al. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. J Immunother Cancer. 2014 Jul 7;2:21. [3]. Chen Y, et al. An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy. Nat Commun. 2016 Nov 7;7:13443 |
分子式 |
C18H21FN2O2
|
|
---|---|---|
分子量 |
316.38
|
|
CAS号 |
1402837-78-8
|
|
相关CAS号 |
IDO-IN-5;1402837-79-9;IDO-IN-6;1402837-76-6;IDO-IN-8;1402837-77-7
|
|
SMILES |
O[C@@H]([ C@H]1CC[ C@H](O)CC1)C[C@@H](C2=C3C=CC=C2F)N4C3=CN=C4
|
|
化学名 |
|
|
别名 |
|
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
|
|||
---|---|---|---|---|
溶解度 (体内) |
Solubility in Formulation 1: ≥ 3 mg/mL (9.48 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3 mg/mL (9.48 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3 mg/mL (9.48 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.5 mg/mL (7.90 mM) (saturation unknown) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 5: ≥ 2.5 mg/mL (7.90 mM) (saturation unknown) in 5% DMSO + 95% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 6: ≥ 0.5 mg/mL (1.58 mM) (saturation unknown) in 1% DMSO 99% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 3.1608 mL | 15.8038 mL | 31.6076 mL | |
5 mM | 0.6322 mL | 3.1608 mL | 6.3215 mL | |
10 mM | 0.3161 mL | 1.5804 mL | 3.1608 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
Figure 1 n vitrobiological activities of PEG2k-Fmoc-NLG.Nat Commun. 2016 Nov 7;7:13443. th> |
---|
In vivobiological activities of PEG2k-Fmoc-NLG.Nat Commun. 2016 Nov 7;7:13443. td> |
IDO-blockade synergizes with chemo-radiation therapy. td> |
Inhibition or absence of IDO triggers widespread complement deposition in tumors after chemo-radiation therapy.J Immunother Cancer. 2014 Jul 7;2:21. th> |
---|
Dose-dependent antitumor efficacy ofNLG919.Int J Immunopathol Pharmacol.2017 Sep;30(3):215-226. td> |
Combinatorial treatment withNLG919and paclitaxel.J Immunother Cancer. 2014 Jul 7;2:21. NLG919increased the sensitivity of B16-F10 cells to paclitaxel after treatment with IFN-γ.Int J Immunopathol Pharmacol.2017 Sep;30(3):215-226. td> |